S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
Critical asset just had biggest fall on record (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: World markets are lower after China unveils 5% economic growth target for 2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities
S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
Critical asset just had biggest fall on record (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: World markets are lower after China unveils 5% economic growth target for 2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities
S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
Critical asset just had biggest fall on record (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: World markets are lower after China unveils 5% economic growth target for 2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities
S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
Critical asset just had biggest fall on record (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: World markets are lower after China unveils 5% economic growth target for 2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities

NeuroBo Pharmaceuticals (NRBO) News Today

$6.52
+0.28 (+4.49%)
(As of 03/4/2024 ET)
SourceHeadline
finanznachrichten.de logoNeuroBo Pharmaceuticals, Inc.: NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer
finanznachrichten.de - March 4 at 11:30 AM
msn.com logoNeuroBo Pharmaceuticals appoints Marshall Woodworth as CFO
msn.com - March 4 at 11:30 AM
markets.businessinsider.com logoNeuroBo Pharmaceuticals Confirms Marshall Woodworth As New CFO
markets.businessinsider.com - March 4 at 11:30 AM
finance.yahoo.com logoNeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer
finance.yahoo.com - March 4 at 11:30 AM
markets.businessinsider.com logoNeuroBo Receives First Site IRB Approval For DA-1726 Obesity Trial; Stock Gains
markets.businessinsider.com - February 29 at 10:20 AM
prnewswire.com logoNeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
prnewswire.com - February 29 at 8:01 AM
finance.yahoo.com logoNeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference
finance.yahoo.com - February 12 at 9:54 AM
finance.yahoo.com logoNRBO: Initiating Coverage of NeuroBo Pharmaceuticals, Inc.; Targeting the $30 Billion+ Obesity Market…
finance.yahoo.com - February 6 at 4:09 PM
msn.com logoNeuroBo’s DA-1726 Obesity Therapy Gets FDA IND Approval
msn.com - February 2 at 8:33 AM
msn.com logoWhy Obesity-Drug Maker NeuroBo Stock Is Trading Higher
msn.com - February 1 at 1:03 PM
markets.businessinsider.com logoNeuroBo Pharma'a IND Application For DA-1726 Gets FDA Clearance
markets.businessinsider.com - February 1 at 1:03 PM
markets.businessinsider.com logoNeuroBo Rises 48% On Receiving FDA Approval For IND Application For DA-1726
markets.businessinsider.com - February 1 at 1:03 PM
msn.com logoNeuroBo to begin Phase 1 testing of potential Wegovy rival
msn.com - February 1 at 1:03 PM
finance.yahoo.com logoNeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
finance.yahoo.com - February 1 at 1:03 PM
investing.com logoNeurobo Pharmaceuticals Inc (NRBO)
investing.com - January 30 at 7:24 AM
markets.businessinsider.com logoNeuroBo Announces Positive Pre-Clinical Safety Data Of DA-1241 In Combination With Sitagliptin
markets.businessinsider.com - January 18 at 1:15 PM
finance.yahoo.com logoNRBO: Initiating Coverage of NeuroBo Pharmaceuticals, Inc.; Targeting the $30 Billion+ Obesity Market…
finance.yahoo.com - January 18 at 1:15 PM
finance.yahoo.com logoNeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
finance.yahoo.com - January 18 at 8:14 AM
finanznachrichten.de logoNeuroBo Pharmaceuticals, Inc.: NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement
finanznachrichten.de - January 9 at 1:08 PM
finance.yahoo.com logoNeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement
finance.yahoo.com - January 9 at 1:08 PM
finance.yahoo.com logoNeuroBo to Participate in Industry and Investor Conferences in January
finance.yahoo.com - January 2 at 10:16 AM
msn.com logoWhat's Going On With Clinical-Stage Biotech Firm NeuroBo Shares Today?
msn.com - December 29 at 10:24 AM
benzinga.com logoNeuroBo Pharmaceuticals Stock (NASDAQ:NRBO), Short Interest Report
benzinga.com - December 28 at 1:18 PM
markets.businessinsider.com logoNeuroBo Submits IND Application For Phase 1 Clinical Trial Of DA-1726; Stock Up In Pre-market
markets.businessinsider.com - December 28 at 1:18 PM
finance.yahoo.com logoNeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
finance.yahoo.com - December 28 at 1:18 PM
benzinga.com logoNeuroBo Pharmaceuticals Stock (NASDAQ:NRBO) Dividends: History, Yield and Dates
benzinga.com - December 27 at 3:38 PM
marketbeat.com logo
marketbeat.com - December 21 at 6:05 AM
finance.yahoo.com logoNeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Split
finance.yahoo.com - December 19 at 1:35 PM
finance.yahoo.com logoNeuroBo to Participate in Investor Conferences in December
finance.yahoo.com - December 1 at 10:33 AM
finanznachrichten.de logoNeuroBo Pharmaceuticals, Inc.: NeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
finanznachrichten.de - November 14 at 7:07 PM
msn.com logoNeuroBo Pharmaceuticals GAAP EPS of -$0.09 beats by $0.02
msn.com - November 13 at 7:36 PM
finance.yahoo.com logoNeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
finance.yahoo.com - November 13 at 7:36 PM
finance.yahoo.com logoNeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D.
finance.yahoo.com - November 6 at 1:02 PM
finance.yahoo.com logoNeuroBo to Present at the H.C. Wainwright 7th Annual NASH Investor Conference
finance.yahoo.com - October 17 at 9:06 AM
finance.yahoo.com logoNeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH
finance.yahoo.com - September 15 at 8:20 AM
finanznachrichten.de logoNeuroBo Pharmaceuticals, Inc.: NeuroBo Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
finanznachrichten.de - August 16 at 5:29 PM
markets.businessinsider.com logoNeuroBo Appoints Hyung Heon Kim As CEO
markets.businessinsider.com - August 14 at 5:32 PM
finance.yahoo.com logoNEUROBO PHARMACEUTICALS APPOINTS HYUNG HEON KIM AS CHIEF EXECUTIVE OFFICER AND PRESIDENT
finance.yahoo.com - August 14 at 8:07 AM
finance.yahoo.com logoNeuroBo Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
finance.yahoo.com - August 9 at 7:41 PM
finance.yahoo.com logoNeuroBo Pharmaceuticals Receives First Site IRB Approval for its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH
finance.yahoo.com - August 3 at 9:26 AM
finance.yahoo.com logoNeuroBo Pharmaceuticals Enters Into Term Sheet With MThera Pharma to Out-license NB-01
finance.yahoo.com - August 2 at 9:36 AM
msn.com logoNeuroBo Pharma Says Its Weight Loss Candidate Outperforms Major Competitors in Preclinical Obesity Study
msn.com - June 27 at 3:31 PM
finance.yahoo.com logoNeuroBo Pharmaceuticals' Novel GLP1R and GCGR Dual Agonist, DA-1726, Shown to Elicit Superior Weight Loss Efficacy Compared to Semaglutide and Tirzepatide in Preclinical Models
finance.yahoo.com - June 27 at 10:30 AM
fool.com logoNeuroBo Pharmaceuticals (NASDAQ: NRBO)
fool.com - June 24 at 12:52 AM
finance.yahoo.com logoNeuroBo Pharmaceuticals Announces Acceptance of Two General Posters and One ePoster Theater Discussion of its Novel GLP1R and GCGR Dual Agonist, DA-1726, at the American Diabetes Association 83rd Scientific Sessions
finance.yahoo.com - June 13 at 5:32 PM
forbes.com logoTeva Pharmaceutical Inds
forbes.com - June 13 at 8:04 AM
finance.yahoo.com logoHere's Why NeuroBo Pharmaceuticals, Inc. (NRBO) Could be Great Choice for a Bottom Fisher
finance.yahoo.com - June 6 at 1:48 PM
finance.yahoo.com logoNeuroBo Pharmaceuticals, Inc. Appoints Pharmaceutical Industry Executive, Mark A. Glickman, to its Board of Directors
finance.yahoo.com - May 12 at 8:59 AM
finance.yahoo.com logoNeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 2a Clinical Trial of DA-1241 for the Treatment of NASH
finance.yahoo.com - May 2 at 9:44 AM
finance.yahoo.com logoNeuroBo Pharmaceuticals Announces Submission of IND Application to the FDA for a Phase 2a Clinical Trial of DA-1241 for the Treatment of NASH
finance.yahoo.com - April 3 at 10:39 AM
Get NeuroBo Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for NRBO and its competitors with MarketBeat's FREE daily newsletter.



NRBO Media Mentions By Week

NRBO Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

NRBO
News Sentiment

0.41

0.64

Average
Medical
News Sentiment

NRBO News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

NRBO Articles
This Week

8

1

NRBO Articles
Average Week

Get NeuroBo Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for NRBO and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:NRBO) was last updated on 3/5/2024 by MarketBeat.com Staff